All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Swaminathan presented a poster during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, reporting long-term findings of a phase II study (NCT03404193) of venetoclax in combination with 10-day decitabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). |
Key learnings |
Among patients with newly diagnosed (ND) AML (n = 88), untreated secondary AML (sAML; n = 17), treated sAML (n = 30), relapsed/refractory (R/R) AML (n = 72), and high-risk MDS (n = 21):
|
Among patients with ND AML, untreated sAML, treated sAML, and R/R AML:
|
Patients receiving stem cell transplantation (SCT) had improved survival outcomes compared with those not receiving SCT. |
Safety findings were consistent with the known safety profile of venetoclax + hypomethylating agents. Most common treatment-emergent adverse events were infection with absolute neutrophil count <1.0 × 109/L (42%) and >1.0 × 109/L (38%), febrile neutropenia (32%), thrombocytopenia (16%), neutropenia (13%), and oral mucositis (13%). |
Venetoclax in combination with 10-day decitabine was highly effective and well tolerated in older/unfit patients with ND and R/R AML; however, more clinical trials are needed to validate the findings. |
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox